Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | CCR1 | P32246 | 3/20 | 0.40 |
| ▸ | CCR5 | P51681 | 3/20 | 0.40 |
| ▸ | CCR8 | P51685 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | MMP2 | P08253 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GMNN | O75496 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | THPO | P40225 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylamine SCHEMBL11033934 | 0.90 | HTR2A (0.34) | LMNACCR1CCR5CCR8CYP3A4 | |
| SCHEMBL17511986 | 0.84 | LMNA (0.31) | LMNA | |
| SCHEMBL11499049 | 0.82 | LMNA (0.31) | LMNACCR1CCR5CCR8CYP3A4 | |
| SCHEMBL3586683 | 0.78 | CCR1 (0.64) | LMNACCR1CCR5CCR8CYP3A4 | |
| SCHEMBL1451059 | 0.77 | LMNA (0.56) | LMNACCR1CCR5CCR8CYP3A4 | |
| SCHEMBL194481 | 0.76 | LMNA (0.43) | LMNACCR1CCR5CCR8CYP3A4 | |
| SCHEMBL8673305 | 0.74 | LMNA (0.37) | LMNACYP3A4KDM4EMAPTHTT | |
| SCHEMBL3820324 | 0.72 | LMNA (0.43) | LMNACCR1CCR5CCR8CYP3A4 | |
| SCHEMBL21001801 | 0.72 | LMNA (0.61) | LMNACCR1CCR5CCR8CYP3A4 | |
| SCHEMBL157930 | 0.72 | LMNA (0.61) | LMNACCR1CCR5CCR8CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 459 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250073207-A1 | PSILOCIN BENZOATE FORMULATION FOR INTRAVENOUS INFUSION | ELEUSIS THERAPEUTICS US, INC. | 2025-03-06 | — | — | US | claimed |
| EP-4463153-A1 | PSILOCIN BENZOATE FORMULATION FOR INTRAVENOUS INFUSION | Eleusis Therapeutics US, Inc. (US) | 2024-11-20 | — | — | EP | claimed |
| CN-118108723-A | Triazolobenzodiazepine compound and preparation method and application thereof | 暨南大学附属第一医院（广州华侨医院） | 2024-05-31 | — | — | CN | claimed |
| US-20230277568-A1 | METHOD OF TREATMENT FOR PSILOCYBIN OR PSILOCIN INFUSION | ELEUSIS THERAPEUTICS US, INC. | 2023-09-07 | — | — | US | claimed |
| WO-2023137094-A1 | PSILOCIN BENZOATE FORMULATION FOR INTRAVENOUS INFUSION | ELEUSIS THERAPEUTICS US, INC. (US) | 2023-07-20 | — | — | WO | claimed |
| EP-4178569-A1 | METHOD OF TREATMENT FOR PSILOCYBIN OR PSILOCIN INFUSION | Eleusis Therapeutics US, Inc. (US) | 2023-05-17 | — | — | EP | claimed |
| WO-2022082058-A1 | METHOD OF TREATMENT BY TRYPTAMINE ALKALOIDS | ELEUSIS THERAPEUTICS US, INC. (US) | 2022-04-21 | — | — | WO | claimed |
| WO-2022011350-A1 | METHOD OF TREATMENT FOR PSILOCYBIN OR PSILOCIN INFUSION | ELEUSIS THERAPEUTICS US, INC. (US) | 2022-01-13 | — | — | WO | claimed |
| US-11154537-B2 | Method of treatment for ketamine infusion | ELEUSIS THERAPEUTICS US, INC. (US) | 2021-10-26 | — | — | US | claimed |
| US-20210322384-A1 | Method of Treatment for Ketamine Infusion | ELEUSIS THERAPEUTICS US, INC. (US) | 2021-10-21 | — | — | US | claimed |
| EP-2186515-A1 | PHARMACEUTICAL COMPOSITION COMPRISING THE COMBINATION OF AN ANTI-DEPRESSIVE AGENT AND AN ANSIOLYTIC AGENT FOR CONTROL AND TREATMENT OF DEPRESSIVE DISORDERS | World Trade Import-Export, WTIE A.G. (CH) | 2010-05-19 | — | — | EP | claimed |
| EP-2168584-A1 | PHARMACEUTICAL COMPOSITION COMPRISING THE COMBINATION OF A TRIAZOLOBENZODIAZEPINE AND A SELECTIVE SEROTONIN REUPTAKE INHIBITOR | World Trade Import-Export, WTIE A.G. (CH) | 2010-03-31 | — | — | EP | claimed |
| US-6572848-B1 | For example taurine, gamma-aminobutyric acid (GABA), isoguvacin, isonipecotic acid, 4,5,6,7-tetrahydroisoxazolo-(5,4-c)pyrid- 3(2H)-one, a benzodiazepine, steroids, and cromakalim, pinacidil, | SOCIETE L'OREAL S.A. (FR) | 2003-06-03 | — | — | US | claimed |
| US-6277846-B1 | ADMINISTERING TO MAMMAL AN ANTIHISTAMINE-FREE ANTIALLERGENIC AGENT WITH SIDE EFFECT REDUCTION | ALLERGAN SALES, INC. | 2001-08-21 | — | — | US | claimed |
| EP-0532512-B1 | USE OF PLATELET ACTIVATING FACTOR ANTAGONISTS AS ANTI-PRURITIC AGENTS | ALLERGAN INC (US) | 1996-12-11 | — | — | EP | claimed |
| EP-0532512-A4 | USE OF PLATELET ACTIVATING FACTOR ANTAGONISTS AS ANTI-PRURITIC AGENTS | — | 1993-05-05 | — | — | EP | claimed |
| EP-0532512-A1 | USE OF PLATELET ACTIVATING FACTOR ANTAGONISTS AS ANTI-PRURITIC AGENTS. | ALLERGAN INC (US) | 1993-03-24 | — | — | EP | claimed |
| WO-1991018608-A1 | USE OF PLATELET ACTIVATING FACTOR ANTAGONISTS AS ANTI-PRURITIC AGENTS | ALLERGAN, INC. (US) | 1991-12-12 | — | — | WO | claimed |
| EP-0127417-B1 | PROCESS FOR PREPARING 1-DIMETHYLAMINOMETHYL-TRIAZOLOBENZODIAZEPINES | THE UPJOHN COMPANY (US) | 1987-05-13 | — | — | EP | claimed |
| US-4110337-A | ANALGESIC, ANTIINFLAMMATORY | LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1978-08-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11154537-B2 | Method of treatment for ketamine infusion | KCND2, KCND3, KCNH3 | LMNA 967/4885CCR1 3000/4885CCR5 2243/4885 |
| US-20250073207-A1 | PSILOCIN BENZOATE FORMULATION FOR INTRAVENOUS INFUSION | SRI, PROC, PRDX6 | LMNA 1259/4885CCR1 4471/4885CCR5 3200/4885 |
| US-20210322384-A1 | Method of Treatment for Ketamine Infusion | KCND2, KCND3, KCNH3 | LMNA 967/4885CCR1 3000/4885CCR5 2243/4885 |
| US-20230277568-A1 | METHOD OF TREATMENT FOR PSILOCYBIN OR PSILOCIN INFUSION | PNN, HTR1B, GABBR1 | LMNA 506/4885CCR1 1939/4885CCR5 1259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.